Amgen (AMGN) Stock
Large biotech company with established medicines and steady dividends. Here's the price, business snapshot, and what's worth knowing about Amgen in August 2026.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It’s Moving
Amgen’s strong earnings haven’t erased analyst caution as valuation pressure keeps downside risk in focus.
- Amgen’s latest quarterly report showed revenue up 10% to $10.1 billion and adjusted EPS above expectations, but the market is now focused on whether that momentum can keep up after the post-earnings run.
- Analysts are still signaling downside because the stock has moved close to its highs, making valuation look stretched even after strong results.
- Recent chatter around insider share sales and a still-mixed analyst stance has added to the caution, suggesting some investors are locking in gains rather than chasing the move.
Amgen’s strong earnings haven’t erased analyst caution as valuation pressure keeps downside risk in focus.
- Amgen’s latest quarterly report showed revenue up 10% to $10.1 billion and adjusted EPS above expectations, but the market is now focused on whether that momentum can keep up after the post-earnings run.
- Analysts are still signaling downside because the stock has moved close to its highs, making valuation look stretched even after strong results.
- Recent chatter around insider share sales and a still-mixed analyst stance has added to the caution, suggesting some investors are locking in gains rather than chasing the move.
About This Stock
AMGEN INC
AMGN
Current Price
$443.54
Potential 12 Month Profit
-21.07%
Sector
Healthcare
Industry
Pharmaceuticals
Ticker
AMGN
Market Cap
$239.09B
Potential 12 Month Profit
-21.07%
Sector
Healthcare
Industry
Pharmaceuticals
Sixth Month Growth Performance
next-earnings-question
The next AMGN earnings date is expected to be November 3, 2026, based on the company’s historical reporting pattern. This report should cover Q3 2026 results. Amgen has not publicly confirmed the date yet, so the timing remains estimated.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Amgen's stock with a target price of $354.97, indicating limited potential upside.
Financial Health
Amgen is performing well with strong profits, cash flow, and revenue, indicating solid overall health.
Dividend
Amgen's dividend yield of 2.18% is decent for investors seeking income, but it's not very high. If you invested $1000 you would be paid $21.80 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
